Bangladesh Pharmaceutical Market Had a Valuation of US$700mn in 2007 and That a Compound Annual Growth Rate (CAGR) Of 18.79% through To 2012 Can Be Expected.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/bf1f27/bangladesh_pharmac) has announced the addition of the "Bangladesh Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.

Bangladesh Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Bangladesh's pharmaceuticals and healthcare industry.

The Bangladesh Pharmaceuticals & Healthcare Report Q308 is the most recent addition to BMI's Industry Survey & Forecasts Series. It integrates data and narrative from market research firms, industry associations and company presentations to provide objective assessment of one of Asia Pacific's most promising opportunities for drugmakers.

We calculate that the country's pharmaceutical market had a valuation of US$700mn in 2007 and that a compound annual growth rate (CAGR) of 18.79% through to 2012 can be expected. This rapid market expansion is primarily due to greater uptake of medicine throughout this densely populated country, but also through appreciation of the data against the US dollar, population growth and increased government healthcare expenditure, among other factors.

2008 is proving a challenging year for drugmakers in Bangladesh. A round of price cuts is scheduled after a hiatus of two years. Sales forces of Bangladeshi drugmakers are growing exponentially, which results in significantly higher expenses. Meanwhile, the appreciation of both the Indian rupee and the Chinese yuan is boosting the cost of raw materials.

Eskayef was best performing company in Bangladesh during Q108, with sales up 21.12% on Q107, according to IMS Health. This compares favourably to the next fastest growing drugmakers: Renata (+16.19%), ACI (+16.17%) and Drug International (+13.79%), Incepta Pharma (+6.77%) and Square Pharma (+2.32%). Not all Bangladeshi pharmaceutical companies performed so well. Beximco Pharma witnessed a huge 42.04% drop in sales, while Acme recorded a 4.89% decrease.

The greatest challenge facing the industry is the end of the patent-free regime in 2016, when local pharmaceutical companies will have to cease the production, distribution and sale of medicine that have intellectual property protection elsewhere in the world. Forward thinking local drugmakers will have to adapt their product portfolio as necessary or suffer a steep drop-off in sales. However, the global 'patent cliff' in 2011 will mitigate this watershed.

Key Topics Covered:

Executive Summary

Bangladesh Pharmaceuticals And Healthcare Industry SW

Bangladesh Political SWOT

Bangladesh Economic SWOT

Bangladesh Business Environment SWOT

Pharmaceutical Business Environment Ratings

Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q308

Limits To Potential Returns

Risks To Realisation Of Returns

Market Summary

Regulatory Regime

Table: Steps Required To Establish Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence (DML)

Counterfeit Drugs 

Intellectual Property

Pricing And Reimbursement Regime

Industry Trends And Developments

Epidemiology

Healthcare Sector

Recent Activities By Foreign Companies

Contract Manufacturing

Research And Development

Table: Suggestions Made By University Of Dhaka's Faculty Of Pharmacy To Improve Pharmaceutical Research Standards

Industry Forecast Scenario

Overall Market Forecast

Table: Bangladeshi Drug Market Expenditure, 2003-2012

Key Growth Factors - Industry

Key Growth Factors - Macroeconomic 

Table: Bangladesh - Economic Activity

Prescription Drug Market Forecast

Table: Bangladeshi Prescription Drug Market - Data And Forecasts (BDTmn, unless otherwise stated)

Patented Drug Market Forecast

Table: Bangladeshi Patented Drug Market - Data And Forecasts

Generics Market Forecast

Table: Bangladeshi Generics Market - Data And Forecasts

OTC Drug Market Forecast

Table: Bangladeshi OTC Drug Market - Data And Forecasts (BDTmn, unless otherwise stated)

Pharmaceutical Export/Import Forecast

Table: Bangladeshi Pharmaceutical Export/Import - Data And Forecast (US$mn)

Other Healthcare Data Forecasts

Table: Other Healthcare Data And Forecasts

Key Risks To BMI's Forecasts

Competitive Landscape

Company Profiles

Eskayef Bangladesh

Square Pharmaceuticals

Renata

Beximco Pharmaceuticals

BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Business Environment Ratings Methodolo

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Companies Mentioned:

- Eskayef Bangladesh

- Square Pharmaceuticals

- Renata

- Beximco Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/bf1f27/bangladesh_pharmac